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Abstract
Saponins are a group of naturally occurring plant glycosides which possess a wide range of pharmacological properties,
including anti-tumorigenic and antiviral activities. To investigate whether saponin has anti-hepatitis C virus (HCV) activity,
we examined the effect of saponin on HCV replication. HCV replication was efficiently inhibited at a concentration of 10 mg/
ml of saponin in cell culture grown HCV (HCVcc)-infected cells. Inhibitory effect of saponin on HCV replication was verified
by quantitative real-time PCR, reporter assay, and immunoblot analysis. In addition, saponin potentiated IFN-a-induced anti-
HCV activity. Moreover, saponin exerted antiviral activity even in IFN-a resistant mutant HCVcc-infected cells. To investigate
how cellular genes were regulated by saponin, we performed microarray analysis using HCVcc-infected cells. We
demonstrated that suppressor of cytokine signaling 2 (SOCS2) protein level was distinctively increased by saponin, which in
turn resulted in inhibition of HCV replication. We further showed that silencing of SOCS2 resurrected HCV replication and
overexpression of SOCS2 suppressed HCV replication. These data imply that saponin inhibits HCV replication via SOCS2
signaling pathway. These findings suggest that saponin may be a potent therapeutic agent for HCV patients.
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Introduction
Hepatitis C virus (HCV) is a major cause for chronic liver
disease leading to liver cirrhosis and hepatocellular carcinoma
(HCC) [1]. More than 170 million people worldwide are infected
with HCV. HCV is an enveloped, positive-sense RNA virus
classified in the Hepacivirus genus within the Flaviviridae family.
HCV has been classified into six major genotypes and numerous
subtypes [2–4]. HCV genome encodes a single polyprotein
precursor of more than 3,010 amino acids, which is cleaved into
structural (core, E1, and E2) and nonstructural (p7, NS2 to NS5B)
proteins by host and viral proteases at the endoplasmic reticulum.
A vaccine is not yet available and the only licensed therapy for
patients infected with HCV is a combination of the pegylated
interferon (IFN)-a and ribavirin. The therapy with these agents is
associated with various adverse effects and achieves a sustained
virological response (SVR) with significant differences among
genotypes [5]. Although two inhibitors of HCV protease,
boceprevir (Victrelis
TM) and telaprevir (Incivek
TM), are recently
approved by the Food and Drug Administration, these drugs are
only effective in combination with peginterferon alpha and
ribavirin. Furthermore, small molecule inhibitors of HCV RNA
polymerase are in clinical trial stages, the error prone nature of the
viral RNA polymerase leads to rapid emergence of viral-resistant
mutations to these therapeutic candidates [6]. Therefore, herbal
medicine could be an alternative approach to control HCV
propagation. It has been reported that catechin, glycyrrhizin,
silymarin and phytosterol showed efficacy in therapy of chronic
hepatitis [7]. Proanthocyandin, purified from blueberry leaves,
inhibited viral replication in HCV-infected patients [8]. Recently,
it has been reported that the laccase, an extract from oyster
mushroom, suppressed HCV entry into peripheral blood cells and
hepatoma cells [9]. Furthermore, Hussein et al. reported that
medicinal plant extracts from Acacia nilotica, Boswellia carterii,
Embelia schimperi, Piper cubeba, Quercus infectoria, Trachyspermum ammi,
and Syzygium aromaticum significantly inhibited HCV protease
activity in vitro [10].
Saponins are mainly produced by plants but also by lower
marine animals and some bacteria [11,12]. Saponins possess a wide
range of pharmacological properties, including anti-carcinogenic,
anti-inflammatory, and anti-viral activities. HIV-1 replication was
inhibited by triterpenoid sapogenin oleanolic acid, which probably
decreased the HIV-1 protease activity. In addition, some
triterpenoidal saponins have been reported to show anti-herpes
simplex virus type 1 (HSV-1) activity [13,14]. In the present study,
we investigated whether saponin exhibited anti-HCV activity in
HCVcc-infected cells. We performed microarray analysis using
HCVcc-infected cells to examine which cellular gene expressions
were modulated by saponin. Of deregulated genes, suppressor of
cytokine signaling 2 (SOCS2) level was increased ,6 times by
saponin treatment as compared to the untreated control. We
showed that saponin inhibited HCV propagation by up-regulating
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39366SOCS2 protein level. Silencing of SOCS2 thereby restored HCV
propagation in HCV-infected cells. These data suggest that
saponin may be a potential candidate for anti-HCV therapeutic
agent.
Materials and Methods
Cell Culture and Transfection
All cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), and 100 units/ml of penicillin-streptomycin in 5% CO2 at
37uC. Huh7 cells harboring HCV subgenomic replicon and IFN-
cured cells were grown as previously reported [15]. For the
transfection experiment, ,5610
5 cells plated on 60-mm dishes
were transfected with plasmid DNA using either Lipofectamine
(Invitrogen) or polyethyleneimine reagent (Sigma) according to the
manufacturer’s instructions. cDNA encoding SOCS2 was pre-
pared from Huh7.5 cells and cloned into p3XFLAG-CMV10
(Sigma) expression vector. The forward primer of SOCS2 was 59-
ATG AAT TCA ATG ACC CTG CGG TGC CTT-39 and
reverse primer was 59-TAT GGA TCC TTA TAC CTG GAA
TTT ATA TTC-39.
Preparation of Infectious Virus
The infectious HCVcc was generated as described previously
[16]. Briefly, HCV RNAs (Jc1, adaptive mutant, IFN-resistant
mutant, JFH1-luc) were generated using T7 RiboMAX
TM Express
Large Scale RNA Productive System (Promega) according to the
manufacturer’s protocols. Approximately, 7.5610
6 Huh7.5 cells (a
gift from Dr. Charles M. Rice, Rockefeller University) were
resuspended in 400 ml of cytomix solution containing 2 mM ATP
and 5 mM glutathione, mixed with 10 mgo fin vitro transcribed
HCV RNA in a 4-mm gap cuvette, and then electroporated at
300 V and 975 mF using a GenePulser II electroporator (Bio-Rad).
Cells were gently transferred to complete medium (low glucose
DMEM containing 10% FBS, 100 units/mL penicillin, 100 mg/
mL streptomycin, 2 mM L-glutamine, 1 mM NEAA and 10 mM
HEPES) and plated on a 150-mm dish. At 24 h later, the medium
was replaced with the fresh complete medium to remove cell
debris. The culture medium was collected at 4 days after
electroporation, filtered through a 0.45-mm filter unit, and kept
as a virus stock. The culture supernatant harvested from cells
transfected with Jc1/GNN mutant RNA was prepared as de-
scribed above and used as a mock infection.
Cytotoxicity Assay
Host cell viability at various concentrations of saponin
(CALBIOCHEM, Germany) was determined using EZ-CyTox
cell viability assay kit (DAEILLAB, Korea) according to the
manufacturer’s protocol.
Immunoblot Analysis
Cells were harvested and lysed in cell lysis buffer containing
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40,
1 mM EDTA, 0.25% sodium deoxycholate, 1 mM Na3VO4,
1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride,
1m M b-glycerophosphate, and protease inhibitor mixture
(Roche) for 15 min on ice. The cell lysates were further
centrifuged at 15,0006g for 15 min at 4uC. The protein
concentration was determined by the Bradford assay (Bio-Rad).
Equal amounts of proteins were subjected to either 8% or 15%
SDS-PAGE and electrotransferred to a nitrocellulose membrane.
The membrane was blocked in PBS containing 5% nonfat dry
milk for 1 h and then incubated 2 h at room temperature with one
of following primary antibodies: rabbit anti-NS3 and anti-NS5A
sera [17], anti-SOCS2 and SOCS3 antibodies (Epitomics), anti-
STAT1 antibody (Santa Cruz), anti-p-STAT1 antibody (Cell
Signaling), and anti-b actin antibody (Sigma) in Tris-buffered
saline/Tween (20 mM Tris-HCl (pH 7.5), 500 mM NaCl, and
0.05% Tween 20). Following two washes in Tris-buffered saline/
Tween 20, the membrane was incubated with either horseradish
peroxidase-conjugated goat anti-rabbit antibody or goat anti-
mouse antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA) in Tris-buffered saline/Tween 20 for 1 h at room
temperature. Proteins were detected using an ECL kit (Elpis
Biotech, Korea).
Quantification of HCV RNA
RNAs were isolated from HCVcc-infected cells, cell culture
medium, or replicon cells by using RiboEx




TM cDNA synthesis kit (Enzynomics, Korea). cDNA
was amplified with HCV genotype 2a-specific primers (forward,
AGAGCCATAGTGGTCTGCGGAAC; reverse,
CCTTTCGCAACCCAACGCTACTC), HCV genotype 1b-spe-
cific primers (forward, ATCACTCCCCTGTGAGGAACTACT;
reverse, CTGGAGGCTGCACGACACTC), SOCS2-specific pri-
mers (forward, GAGCTCGGTCAGACAGGATG; reverse,
AGTTGGTCCAGCTGATGTTTT), and GAPDH-specific pri-
mers (forward, CGCTCTCTGCTCCTCCTGTTC; reverse,
CGCCCAATACGACCAAATCCG). All quantitative real-time
PCR (qRT-PCR) experiments were performed by using an iQ5
multicolor real-time PCR detection system (Bio-Rad Laboratories,
Hercules, CA) under the following conditions: 15 minutes at 95uC




was shownas percentage ofHCV RNA.
Reporter Assays
Huh7.5 cells were electroporated with in vitro transcribed JFH1-
Luc RNA. At 48 h after RNA electroporation, cells were treated
with increasing amounts of saponin in the absence or presence of
50 U/ml of IFN-a (Sigma-Aldrich, St. Louis, MO) for 24 h and
then luciferase reporter activities were determined as described
previously [16].
Gene Silencing by siRNA
siRNAs targeting the SOCS2, the 59UTR of HCV (positive
control), and the universal negative control were purchased from
Dharmacon (Lafayette, CO). siRNA transfection was performed
using a Lipofectamine RNAiMax reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
Microarray Analysis
Huh7.5 cells were infected with Jc1 for 4 h and then either left
untreated or treated with 10 mg/ml of saponin. At 24 h after
saponin treatment, cellular RNAs were isolated by using
RiboEx
TM Total RNA (GeneAll Biotechnology, Korea) according
to the manufacturer’s instructions. The extracted RNAs were
labeled using a GeneAtlas
TM 39IVT Express Kit Assay (Affyme-
trix), and hybridized onto Affymetrix Human Genome U219
Array strip that is comprised of more than 530,000 probes
covering over 36,000 transcripts and variants. Raw microarray
data were processed using Partek Express software (Affymetrix
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calculated fold-change value means the ratio of gene expression
level in saponin-treated Jc1-infected cells as compared to the non-
treated Jc1-infected cells. Cellular genes that were either 2-fold up-
regulated or down-regulated by saponin in Jc1-infected cells were
selected as targets for further study.
Results
Saponin Suppresses HCV Propagation in HCVcc-infected
Cells
Saponin exerts antiviral activity against HSV type I [14]. To
investigate whether saponin could exhibit anti-HCV activity, we
first examined the effect of saponin on HCV propagation. Huh7.5
cells were either mock-infected or Jc1-infected (genotype 2a) and
then treated with various concentrations of saponin. As shown in
Fig. 1A, saponin inhibited HCV protein expression in a dose-
dependent manner. It was noteworthy that HCV protein
expression levels were significantly inhibited with 10 mg/ml of
saponin (Fig. 1A, 1B). To determine whether the inhibitory effect
of saponin on HCV protein expression was caused by cytotoxicity
of saponin, cellular viability was analyzed by cytotoxicity assay.
We found that 20 mg/ml of saponin exerted no cytotoxicity in
HCVcc-infected cells (data not shown). To further investigate
whether higher dosages of saponin might increase anti-HCV
activity, HCVcc-infected cells were treated with either 50 mg/ml
or 100 mg/ml of saponin and then resultant HCV protein
expression and cell viability were analyzed. Indeed, HCV protein
levels were decreased 95% at 50 mg/ml and 99% at 100 mg/ml of
saponin, respectively (Fig. S1). However, cell viability was also
decreased by 20% and 30% at 50 mg/ml and 100 mg/ml of
saponin, respectively. These results suggest that 10 to 20 mg/ml of
saponin is the optimum concentration to inhibit HCV replication
without affecting cellular growth. The half maximal inhibitory
concentration (IC50) for saponin to inhibit HCV replication was in
the range of 7–18 mg/ml of saponin in general (Fig. S2). We
further showed that cellular toxicity value (CC50) of saponin was
165.72 mg/ml and selective index was considered significant (Fig.
S2). To determine the effect of saponin on HCV RNA level, we
quantified both intracellular HCV RNA level and HCV infectivity
in saponin treated cells. We demonstrated that intracellular HCV
RNA level was significantly reduced by 10 mg/ml of saponin. As
shown in Fig. 1D, HCV infectivity was significantly suppressed by
5 mg/ml of saponin, indicating that saponin inhibits HCV
propagation.
Time Course Effect of Saponin on HCV Propagation
To analyze the time course effect of saponin on HCV
propagation, Huh7.5 cells infected with Jc1 were incubated with
10 mg/ml of saponin for 24 h, 48 h, and 72 h, respectively. As
shown in Fig. 2A, HCV protein expression level was continuously
increased from 24 h to 72 h in the absence of saponin. However,
HCV protein expression was prominently inhibited as early as
24 h after saponin treatment and continued until 72 h. At 72 h
after saponin treatment, HCV protein expression level was
suppressed by ,90% as compared to untreated control (Fig. 2A,
lane 7 versus lane 8). To further analyze both intracellular HCV
RNA level and HCV infectivity during the time course of
experiments, the same set of experiments were performed as
described in the legend to Fig. 2A and HCV RNAs were
quantified by qPCR. Indeed, both intracellular HCV RNA level
(Fig. 2B) and relative HCV infectivity (Fig. 2C) were significantly
decreased with 10 mg/ml of saponin from 24 h to 72 h. These
results confirm that saponin is a potent inhibitor for HCV
replication.
Saponin Suppresses HCV Replication in Replicon Cells
To further investigate whether saponin could suppress viral
replication in other genotype of HCV, we analyzed the effect of
saponin on viral replication using HCV replicon derived from
genotype 1b. Both IFN-cured and subgenomic replicon cells were
either left untreated or treated with increasing amounts of saponin.
At 24 h after saponin treatment, HCV protein levels were
determined by immunoblot analysis. As shown in Fig. 3A, HCV
protein expression levels were suppressed by saponin in a dose
dependent manner. Next, we quantified intracellular HCV RNA
levels by qPCR. Fig. 3B showed that intracellular HCV RNA
levels were significantly decreased by 25 mg/ml of saponin. To
determine whether saponin induced cytotoxicity in Huh7 cells
harboring HCV replicon, cell viability was determined by
cytotoxicity assay. As shown in Fig 3C, cellular toxicity was not
induced by saponin. Although cell viability was slightly decreased
at 50 mg/ml of saponin, this effect was insignificant. These data
indicate that saponin inhibits HCV replication in both genotype
1b (subgenomic replicon cells) and genotype 2a (Jc1-infected cells).
To further examine whether saponin could inhibit other virus of
Flaviviridae family, we investigated JEV-infected BHK cells as we
reported previously [16]. We found that saponin also inhibited
JEV replication (data not shown). We thus speculate that saponin
may not target specific HCV protein. Saponin may exert anti-
HCV activity by modulating cellular signaling as described below.
Saponin Potentiates IFN-a-induced anti-HCV Activity
To explore the possible application of saponin for combination
therapy, we evaluated the anti-HCV potency of saponin in
combination with IFN-a using JFH1-Luc reporter system (Fig. 4A).
To verify the reporter activity first, Huh7.5 cells were electro-
porated with JFH1-Luc RNA, treated with increasing amounts of
saponin, and then luciferase reporter activities were determined.
As shown in Fig. 4B, HCV reporter activities were significantly
decreased by saponin in a dose-dependent manner. Likewise,
NS5A expression level was also decreased in a similar pattern
(Fig. 4B, lower panel). We then examined the combinatorial effect
of both IFN-a and saponin on HCV replication. Huh7.5 cells
electroporated with JFH1-Luc RNA were treated with increasing
amounts of saponin in the absence or presence of IFN-a for 24 h
and then luciferase reporter activities were determined. Fig. 4C
showed that IFN-a significantly decreased HCV reporter activity
and this effect was increased by saponin in a dose-dependent
manner. Importantly, HCV replication was suppressed ,95% by
co-treatment of IFN-a and saponin. Cytotoxicity data indicated
that cell viability was not altered by co-treatment of IFN-a and
saponin (Fig. 4D). To further analyze the effect of co-treatment of
saponin and IFN-a on HCV replication, replicon cells were
treated with either IFN-a alone or in combination with IFN-a and
saponin as indicated. Antiviral effect of co-treatment of saponin
and IFN-a on HCV replication was then analyzed by immuno-
blotting with anti-NS3 antibody. Fig. 4E showed that IFN-a-
induced anti-HCV activity was potentiated by saponin in a dose-
dependent manner.
Saponin Inhibits IFN-a Resistant Mutant HCV Propagation
We previously established a novel HCV clone that acquired
IFN-a resistant phenotype by long-term culturing HCV-infected
cells in the presence of IFN-a [18]. We also generated adaptive
HCV mutant in parallel by culturing HCV-infected cells in the
absence of IFN-a and used as a control. Both adaptive and IFN-
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a resistant clone has additional four amino acid substitution
mutations in the C-terminal coding sequence of NS5A [18]. To
verify the IFN-a resistant phenotype first, Huh7.5 cells were
infected with either control adaptive mutant HCV or IFN-
a resistant mutant HCV and then treated with increasing amounts
of IFN-a. As shown in Fig. 5A, the IFN-a resistant mutant HCV
was highly resistant to IFN-a, whereas the adaptive mutant was
susceptible to IFN-a as determined by NS5A protein level. To
explore the inhibitory effect of saponin on IFN-a resistant mutant,
Huh7.5 cells infected with IFN-a resistant mutant HCV were
treated with various concentrations of saponin. Indeed, HCV
protein expression level was decreased by saponin in IFN-
a resistant mutant albeit the decrease level was less than the
adaptive mutant (Fig. 5B). We then investigated the effects of co-
treatment of IFN-a and saponin on NS5A expression in cells
infected with IFN-a resistant mutant HCV. Fig. 5C showed that
co-treatment of IFN-a and saponin additively inhibited HCV
protein expression in control cells infected with adaptive mutant
(lane 4). Most importantly, co-treatment of IFN-a and saponin
significantly inhibited NS5A protein expression even in cells
infected with IFN-a resistant mutant HCV (Fig. 5C, lane 8). It was
noteworthy that co-treatment of IFN-a and saponin in IFN-a-
resistant mutant HCV-infected cells suppressed NS5A protein
expression as much as in cells infected with adaptive mutant HCV
(Fig. 5C, lane 4 versus lane 8). We further confirmed that HCV
core protein expression was also similarly inhibited by co-
treatment of IFN-a and saponin (data not shown), indicating that
saponin exerted antiviral activity even in IFN-a resistant HCV
clone. To further analyze the effect of saponin on IFN-a resistant
mutant HCV more accurately, we determined intracellular HCV
RNA levels by qRT-PCR. Indeed, HCV RNA levels in IFN-a-
resistant mutant HCV-infected cells were similarly inhibited by co-
treatment of IFN-a and saponin as in cells infected with adaptive
mutant HCV (Fig. 5D). These data strongly suggest that saponin
may be the promising combinatorial therapeutic agent for IFN-
a non-responders.
Figure 1. Saponin inhibits HCV propagation. (A) Saponin inhibits HCV protein expression in a dose-dependent manner. Huh7.5 cells infected
with either HCV Jc1 or mock for 4 h were incubated with the selected amounts of saponin (2.5, 5, 10, and 20 mg/ml) for 24 h. Cells were harvested
and then equal amounts of cell lysates were immunoblotted with anti-NS3 and NS5A antibodies, respectively. b-actin was used as a loading control
for the same amount of cell lysates. (B) Relative viral protein levels in HCV-infected cells treated with the indicated dosage of saponin were
normalized by b-actin. (C) Huh7.5 cells were infected with Jc1 for 4 h and then treated with the indicated amounts of saponin. At 24 h postinfection,
intracellular HCV RNAs were analyzed by qRT-PCR using a primer targeting HCV 59UTR-core. (D) Relative HCV infectivity was determined by focus-
forming units (FFU) as we reported previously [16]. Error bars indicate the standard deviation. * indicates statistical significance (p,0.05) and
** indicates p,0.01 versus control.
doi:10.1371/journal.pone.0039366.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39366Figure 2. Time course effect of saponin on HCV propagation. (A) Huh7.5 cells were infected with Jc1 for 4 h and then treated with 10 mg/ml
of saponin for 24 h, 48 h, and 72 h, respectively. At the indicated time points, HCV protein levels were analyzed by immunoblot analysis using anti-
NS3 and NS5A antibodies, respectively. (B) Intracellular HCV RNAs were quantified by qRT-PCR at the given time intervals. (C) Relative HCV infectivity
was determined by FFU as described above. The results are representative of three independent experiments. Error bars indicate the standard
deviation.
doi:10.1371/journal.pone.0039366.g002
Saponin Inhibits HCV Propagation
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39366Saponin Suppresses HCV Replication by Regulating
SOCS2
To investigate the molecular mechanism of saponin involved in
anti-HCV activity, we screened cellular target genes of saponin in
HCV-infected cells using microarray analysis. Huh7.5 cells were
infected with HCV Jc1 and then either left untreated or treated
with 10 mg/ml of saponin. Total mRNAs were isolated from each
group and were subjected to microarray analysis. As shown in
Table S1, 256 genes were .2-fold up-regulated and 236 genes
were .2-fold down-regulated in saponin treated cells as compared
to the untreated cells. Interestingly, genes involved in signal
transduction pathways were predominantly increased by saponin
and genes involved in energy metabolism were largely decreased
by saponin in HCV-infected cells (Fig. S3). It was noteworthy that
SOCS2 expression level was highly increased (6 times) in saponin-
treated cells as compared to the untreated control in microarray
data. Because SOCS2 has been implicated in the negative
regulation of cytokine signal transduction pathway, we investigat-
ed whether SOCS2 was involved in saponin-mediated inhibition
of HCV replication. Huh7.5 cells were infected with Jc1 and then
treated with 10 mg/ml or 20 mg/ml of saponin. Total cellular
RNAs were extracted and then SOCS2 mRNA level was
quantified by qPCR. As shown in Fig. 6A, SOCS2 mRNA level
was significantly increased by saponin in a dose-dependent
manner in Jc1-infected cells. To further confirm whether saponin
increased SOCS2 protein level, Huh7.5 cells infected with either
mock or Jc1 were either left untreated or treated with the indicated
amounts of saponin for 24 h. Equal amounts of cell lysates were
immunoblotted with the indicated antibodies. Fig. 6B showed that
SOCS2 protein expression level was increased by saponin, which
in turn resulted in decrease of HCV protein expression levels. To
further investigate whether saponin increased SOCS2 level in
HCV subgenomic replicon cells, cells were treated with increasing
amounts of saponin and then SOCS2 mRNA level was quantified
by qPCR. Indeed, saponin significantly increased SOCS2 mRNA
level in HCV replicon cells (Fig. 6C). We also examined SOCS2
protein level in HCV replicon cells. As shown in Fig. 6D, SOCS2
protein level was increased by saponin in a dose-dependent
manner. As expected, HCV protein levels were prominently
decreased by saponin. It has been reported previously that the
SOCS2 induces SOCS3 degradation by forming E3 ligase
complex [19]. We showed that SOCS3 level was higher in
replicon cells than in IFN-cured cells (Fig. 6D, lane 1 versus lane
2). Indeed, SOCS3 level was gradually decreased as SOCS2 level
was increased by saponin (Fig. 6D). Furthermore, silencing of
SOCS3 with siRNA decreased HCV replication (data not shown).
These data imply that saponin may suppress HCV replication via
SOCS2 signal pathway.
SOCS2 Negatively Regulates HCV Propagation
To investigate whether saponin-induced SOCS2 was specifically
involved in HCV propagation, HCV protein expression levels
were analyzed by silencing of SOCS2 in Jc1-infected cells. Fig. 7A
showed that cell viability was not affected by either negative or
SOCS2 siRNA in Huh7.5 cells. We then examined the protein
expression levels of both HCV and SOCS2 in cells transfected
Figure 3. Saponin inhibits HCV replication in Huh7 cells harboring subgenomic HCV replicon. (A) HCV protein expressions were
decreased by saponin. Both IFN-cured and subgenomic replicon cells were either left untreated or treated with 25 and 50 mg/ml of saponin,
respectively. At 24 h after saponin treatment, total cell lysates were immunoblotted with the indicated antibodies. b-actin was used as a loading
control for the same amount of cell lysates. (B) Total cellular RNAs were extracted from HCV replicon cells treated with saponin and intracellular HCV
RNAs were quantified by qRT-PCR. (C) Subgenomic replicon cells were left untreated or treated with 25 and 50 mg/ml of saponin, respectively. At 24 h
after saponin treatment, cell viability was determined by cytotoxicity assay.
doi:10.1371/journal.pone.0039366.g003
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expression was significantly suppressed by saponin via up-
regulating SOCS2 expression (lane 2). Indeed, silencing of SOCS2
expression enhanced HCV protein expression (Fig. 7B, lane 1
versus lane 3). However, HCV protein expressions were no longer
significantly suppressed by saponin in SOCS2 knockdown cells
(Fig. 7B, lane 2 versus lane 4). We further confirmed that saponin
specifically inhibited HCV replication via SOCS2 in replicon cells
(Fig. S4), indicating that SOCS2 played a crucial role in anti-HCV
activity of saponin. To further confirm the effects of SOCS2 on
Figure 4. Saponin potentiates IFN-a induced anti-HCV activity. (A) Genomic organization of JFH1-derived luciferase reporter construct (JFH1-
Luc). (B) Saponin suppresses HCV reporter activity in a dose-dependent manner. Huh7.5 cells were electroporated with JFH1-Luc RNA. At 48 h after
electroporation, cells were treated with increasing amounts of saponin for 24 h and then luciferase reporter activities were determined. Data
represent the mean of three independent experiments. (C) Huh7.5 cells were electroporated with JFH1-Luc RNA and were treated with increasing
amounts of saponin in the absence or presence of 50 U/ml of IFN-a for 24 h and then luciferase reporter activities were determined. (D) Huh7.5 cells
were electroporated with JFH1-Luc RNA and then treated with both saponin and IFN-a as described in the legend to Fig. 4C and cell viability was
determined by cytotoxicity assay. (E) HCV subgenomic replicon cells were treated with either IFN-a alone or in combination with IFN-a and saponin
as indicated. Cell lysates harvested at 36 h postinfection were immunoblotted with anti-NS3 antibody.
doi:10.1371/journal.pone.0039366.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39366Figure 5. Saponin suppresses viral propagation of IFN-a resistant mutant HCV. (A) Verification of IFN-a resistance of the mutant HCV.
Huh7.5 cells were infected with either adaptive mutant HCV or IFN-a resistant mutant HCV for 4 h. The cells were treated with increasing amounts of
IFN-a for 24 h and then total cell lysates were immunoblotted with the indicated antibodies. b-actin was used as a loading control for the same
amount of cell lysates. (B) Saponin suppresses the NS5A expression in cells infected with IFN-a resistant mutant HCV. Huh7.5 cells were infected with
HCV as described in the figure legend to A and then treated with increasing amounts of saponin for 24 h. Total cell lysates were immunoblotted with
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lar HCV RNA levels by qPCR in SOCS2 knockdown cells.
Saponin suppressed both intracellular HCV RNA (Fig. 7C) and
extracellular HCV RNA (Fig. 7D) levels. However, saponin was
unable to suppress both intracellular and extracellular HCV RNA
levels in SOCS2 knockdown cells. To further investigate whether
saponin could inhibit HCV replication by upregulating SCOS2,
both HCV protein and intracellular HCV RNA levels were
analyzed by overexpressing SOCS2 protein in HCV-infected cells.
Indeed, overexpression of SOCS2 significantly suppressed both
HCV protein level (Fig. 7E) and intracellular HCV RNA level
(Fig. 7F). Together, these data indicate that saponin inhibits HCV
propagation via SOCS2 protein and thus SOCS2 plays as
a negative regulator in HCV propagation.
Discussion
Persistent infection is the hallmark of HCV patients. HCV
infection often causes chronic hepatitis, liver cirrhosis, and HCC.
However, neither a protective vaccine nor an effective therapeutic
agent against HCV is available yet. Only available current therapy
is the combination of pegylated IFN and ribavirin. However, this
therapy accompanies a high rate of side effects and SVR varies
with different genotypes of HCV [6,20]. Therefore, there is an
urgent need to develop more effective therapeutic agent against
HCV. Because herbal medicine could be an alternative way to
control HCV propagation, we have investigated the potential anti-
HCV activity of saponin. Herbal medicines or medicinal plants
have been widely used to prevent and treat many diseases. The
the indicated antibodies. (C) Co-treatment of saponin and IFN-a synergistically inhibits HCV replication in cells infected with IFN-a resistant HCV as
similar level as in cells infected with adaptive HCV. Huh7.5 cells were infected with HCV as described in the figure legend to A and then treated with
either 30 U/ml of IFN-a or 20 mg/ml of saponin alone, or in combination with IFN-a and saponin as indicated. Total cell lysates were immunoblotted
with the indicated antibodies. (D) Huh7.5 cells were infected with HCV and then treated with either IFN-a or saponin alone, or in combination with
IFN-a and saponin as described in the figure legend to C. Intracellular HCV RNAs isolated from these cells were analyzed by qRT-PCR.
doi:10.1371/journal.pone.0039366.g005
Figure 6. Saponin inhibits HCV replication by increasing SOCS2 expression level. (A) Huh7.5 cells were infected with Jc1 for 4 h. Cells were
then either left untreated or treated with the indicated amounts of saponin for 24 h. Total cellular RNAs were extracted and then SOCS2 mRNA level
was quantified by qRT-PCR. (B) Huh7.5 cells were infected with either mock or Jc1 for 4 h. The cells were then either left untreated or treated with the
indicated amounts of saponin for 24 h. Equal amounts of cell lysates were immunoblotted with the indicated antibodies. (C) HCV subgenomic
replicon cells were treated with increasing amounts of saponin for 24 h. Total cellular RNAs were extracted and then SOCS2 mRNA level was
quantified by qRT-PCR. (D) Both IFN-cured and subgenomic replicon cells were left untreated or treated with increasing amounts of saponin for 24 h.
Equal amounts of cell lysates were immunoblotted with the indicated antibodies. The protein expression levels were normalized with b-actin.
doi:10.1371/journal.pone.0039366.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39366Figure 7. Saponin inhibits HCV propagation by regulating SOCS2 gene. (A) Huh7.5 cells were treated with either negative or SOCS2 siRNAs.
At 72 h after transfection, cell viability was analyzed by cytotoxicity assay. (B-D) Silencing of SOCS2 impairs inhibitory activity of saponin on HCV
propagation. Huh7.5 cells were transfected with the indicated siRNAs. At 36 h after transfection, cells were infected with HCV Jc1 for 4 h and then
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39366biggest advantage of herbal medicines is that those medicines are
safe and abundant in nature. The naturally occurring flavonoid
silymarin, an extract from Silybum marianum, inhibits hepatic stellate
cell activation that is crucial for fibrogenesis [21]. Moreover,
silymarin exerted inhibitory activities on HCV RNA replication
and hepatic fibrosis in HCV patients [22]. Glycyrrhizin, a major
component of Glycyrrhiza glabra extract, modified glycosylation
and suppressed sialyation of hepatitis B surface antigen (HBsAg),
which inhibited secretion of HBsAg [23]. The risk of the
progression of hepatocellular carcinoma was also reduced 2.5-fold
in chronic hepatitis C patients treated with glycyrrhizin as
compared to the untreated control group [24]. Phyllanthus
amarus plant exhibited therapeutic potential in chronic HBV
carriers by suppressing HBV polymerase activity, HBV mRNA
transcription and replication [25,26]. Interestingly, rhizomes of the
Chinese medicinal herb Rhodiola kirilowii (Regel) Maxim
inhibited HCV NS3 serine protease [27].
Saponin is the major pharmacological constituent in some
plants, including Panax Ginseng and Platycodon grandiflorus. Saponin
has been known to exert antiviral activities in HSV and HIV
[13,14,28]. In the present study, we demonstrated that saponin
strongly inhibited HCV propagation at the levels of intracellular
HCV RNA, protein expression, and extracellular HCV RNA. We
showed that saponin suppressed viral replication in HCV derived
from both genotype 1b (subgenomic replicon) and genotype 2a
(Jc1).
Another major finding was that co-treatment of saponin and
IFN-a was highly effective in suppressing HCV replication. We
demonstrated that co-treatment of saponin and IFN-a suppressed
HCV reporter activity for almost no detectable level at 72 h after
treatment. Moreover, co-treatment of saponin and IFN-a in
Huh7.5 cells infected with IFN-a resistant HCV clone suppressed
HCV replication as drastically as did in IFN-a sensitive HCV.
Because IFN-a therapy accompanies adverse effects in many HCV
patients, co-therapy of saponin and IFN-a would minimize the
adverse effects and thus will increase SVR rate in HCV patients.
Collectively, these data suggest that the combination of IFN-a and
saponin may be the legitimate therapy for IFN non-responders
and thus could be an alternative strategy to elevate the SVR rate
in other HCV genotypes.
To elucidate the molecular mechanism of saponin involved in
anti-HCV activity, we screened cellular target genes of saponin in
Jc1-infected cells using microarray analysis. We showed that
SOCS2 gene expression was up-regulated by saponin. We further
confirmed that SOCS2 expression level was also increased by
saponin in HCV replicon cells. HCV protein expression level was
gradually decreased as SOCS2 level was increased in cells treated
with increasing amounts of saponin. SOCS2 is a member of
suppressor of cytokine signaling family that includes eight
members, and characterized by the presence of a SH2 domain
and C-terminal SOCS box [29]. The SOCS box interacts with
Elongin BC, part of an E3 ubiquitin ligase complex that degrades
target proteins through the ubiquitin pathway [29]. Tannahill et al.
reported that SOCS2 interacted with SOCS3 and degraded
SOCS3 by forming E3 ligase complex using Elongin BC in
SOCS2 transgenic mouse [19]. SOCS3 was induced by HCV core
protein and maintained at relatively high levels in chronic hepatitis
C patients [30]. SOCS family proteins are typically considered as
inhibitors of IFN signaling. However, overexpression of SOCS2
inhibited HCV replication in our study. It has been reported
previously that SOCS1 and SOCS3 displayed an inhibitory
activity toward the activation of STAT1 in response to IFNs [31].
However, overexpression of SOCS2 had no effect on the IFN-
mediated activation of STAT1 or the antiproliferative activity of
IFNs. SOCS2 did not inhibit IFN-, IL-6, and OM-27, induced
Jak/STAT signaling. Furthermore, SOCS2 expression enhanced
the antiproliferative activity of IFNs in the presence of low
concentrations of IFNs. Although SOCS2 is one of the SOCS
family members, it exerts a unique function distinguishable from
SOCS1 and SOCS3.
In the present study, saponin increased SOCS2 level, which in
turn resulted in inhibition of HCV replication by decreasing
SOCS3 level. Although the molecular mechanism of saponin-
induced SOCS2 has not been fully clarified in the present study,
saponin no longer suppresses HCV propagation in SOCS2
knockdown cells. These data imply that SOCS2 is specifically
involved in saponin-mediated HCV suppression and thus SOCS2
is a negative regulator in HCV propagation. Taken together, our
study demonstrated that saponin might be a potential therapeutic
agent for HCV patients.
Supporting Information
Table S1 Identification of cellular genes deregulated by
saponin in HCV-infected cells. Jc1-infected cells were either
left untreated or treated with saponin (10 mg/ml) for 24 h. Total
mRNAs isolated from each group were subjected to microarray
analysis. Either two-fold upregulated (256 genes) or downregulated
(236) genes by saponin in HCV-infected cells as compared to non-
treated control were selected. Data normalization and selection of
fold-changed genes were performed using Gene springGX 7.3
(Agilent technology, USA). Gene ID, accession number, and
functional description are provided.
(XLSX)
Figure S1 Determination of anti-HCV activity at high
concentration of saponin. (A) Huh 7.5 cells were either mock-
infected Jc1-infected for 4 h and then treated with selected
amounts of saponin (10, 50, and 100 mg/ml). Cell lysates
harvested at 24 h after saponin treatment were immunoblotted
with anti-NS5A antibody. (B) Huh7.5 cells treated with the
indicated amounts of saponin were analyzed for viability by
cytotoxicity assay. Relative viral protein levels in HCV-infected
cells treated with the indicated dosage of saponin are means 6
standard errors for three independent experiments.
(TIF)
Figure S2 Determination of IC50 and selective index in
replicon cells and HCV-infected cells. (A) To determine
IC50 of saponin in replicon cells, Huh7 cells harboring HCV
replicon were treated with various concentration of saponin for
24 h and then total RNAs were isolated to perform qRT-PCR
using primer sets of HCV genotype 1b and GAPDH. To
determine IC50 of saponin in HCV-infected cells, Huh7.5 cells
were infected with HCV (Jc1, adaptive mutant JFH1, and IFN
resistant mutant JFH1, respectively) for 4 h and then treated with
treated with 10 mg/ml of saponin for 24 h. Total cell lysates were immunoblotted with the indicated antibodies (B). Both intracellular HCV RNAs (C)
and extracellular HCV RNAs (D) isolated from the culture supernatant were quantified by qRT-PCR. (E, F) Overexpression of SOCS2 suppresses HCV
replication. Huh7 cells were transfected with either empty vector or FLAG-tagged SOCS2 expression plasmid. At 24 h after transfection, cells were
infected with HCV for 4 h. Cell lysates harvested at 48 h postinfection were immunoblotted with the indicated antibodies (E). (F) Huh7 cells were
treated as described in the figure legend to E. Intracellular HCV RNAs were isolated and analyzed by qRT-PCR.
doi:10.1371/journal.pone.0039366.g007
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39366various concentration of saponin for 24 h. Total RNAs extracted
from each sample were quantified by qRT-PCR. GAPDH was
used as a normalization gene for qRT-PCR analysis and data were
shown as percentage of HCV RNA. For JFH1-Luc, Huh7.5 cells
were electroporated with in vitro transcribed JFH1-Luc RNA. At
48 h after RNA electroporation, cells were treated with increasing
amounts of saponin for 24 h and then luciferase reporter activities
were determined. (B) IC50 of saponin was estimated using the line
where the saponin concentration provided 50% inhibition of HCV
RNA in HCV-infected cells. Selective index (SI) was determined
from the ratio of CC50/IC50.C C 50 was calculated as 165.72 mg/
ml. SI.4 is considered significant.
(TIF)
Figure S3 Functional classification of cellular genes
altered by saponin in HCV-infected cells. Jc1-infected cells
were either left untreated or treated with saponin (10 mg/ml) for
24 h. Total mRNAs isolated from each group were subjected to
microarray analysis. Both up-regulated and down-regulated
cellular genes in saponin treated cells as compared to non-treated
cells were classified by molecular functions.
(TIF)
Figure S4 Silencing of SOCS2 impairs inhibitory activ-
ity of saponin on HCV replication in replicon cells. Huh7
cells harboring HCV subgenomic replicon were transfected with
the indicated siRNAs. At 36 h after transfection, cells were treated
with 25 mg/ml of saponin for 24 h. Total cell lysates were
immunoblotted with the indicated antibodies. b-actin was used as
a loading control for the same.
(TIF)
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